Lucid DiagnosticsLUCD +4.85%26 EBITDA Margin % is -1,089.25% as of Mar. 2026. GuruFocus rates LUCD with a GF Score™ of 26/100 and a GF Value™ of $0.81 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Lucid Diagnostics ranks worse than 94% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Lucid Diagnostics's EBITDA for the
three
months ended in Mar. 2026 was $-13.68 Mil. Lucid Diagnostics's Revenue for the
three
months ended in Mar. 2026 was $1.26 Mil. Therefore, Lucid Diagnostics's EBITDA margin for the quarter that ended in Mar. 2026 was -1,089.25%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Lucid Diagnostics EBITDA Margin % Related Terms
Lucid Diagnostics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Lucid Diagnostics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LUCD vs TLSI, INFU, TANAF: EBITDA Margin % Comparison
For the Medical Devices subindustry, Lucid Diagnostics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lucid Diagnostics EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Lucid Diagnostics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lucid Diagnostics (LUCD) has a EBITDA Margin % of -1,089.25% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lucid Diagnostics and its competitors. According to the industry distribution chart, Lucid Diagnostics ranks #767 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 94%.
Is Lucid Diagnostics' EBITDA Margin % too high?
Lucid Diagnostics' current EBITDA Margin % is -1,089.25%. Based on the distribution chart, Lucid Diagnostics ranks #767 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Lucid Diagnostics has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' EBITDA Margin % compare to TLSI and INFU?
According to the Medical Devices & Instruments industry distribution chart, Lucid Diagnostics ranks #767 out of 816 companies for EBITDA Margin %. This places Lucid Diagnostics in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Lucid Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lucid Diagnostics's current EBITDA Margin % is -1,089.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.81, compared to a current price of $1.07 — trading 31.5% above its estimated fair value. The current EBITDA Margin % is -1,089.25%. Lucid Diagnostics' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current EBITDA Margin % is -1,089.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lucid Diagnostics (LUCD) Overvalued in 2026?
Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued.
The current stock price of $1.07 is trading 31.5% above its estimated GF Value™ of $0.81.
GuruFocus considers Lucid Diagnostics to be Significantly Overvalued.
Key valuation signals for LUCD:
EBITDA Margin %: -1,089.25%
GF Value™: $0.81 vs. price of $1.07 (31.5% above fair value)
No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
26GF Score
Get the complete analysis for LUCD
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUCD has been successfully added to your 
